Alterations in ceramide concentration and pH determine the release of reactive oxygen species by Cftr-deficient

Yang Zhang1, Xiang Li, Heike Grassmé

  • 1Department of Molecular Biology, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.

Insights

Ceramide accumulation in cystic fibrosis (CF) lung macrophages impairs their ability to fight Pseudomonas aeruginosa infection by disrupting reactive oxygen species (ROS) production. This study reveals a novel pH-controlled pathway affecting macrophage function in CF.

Area of Science:

  • Cell Biology
  • Immunology
  • Pulmonology

Background:

  • Ceramide accumulation is implicated in cystic fibrosis (CF) pathophysiology.
  • The role of ceramide in lung macrophages in CF remains unclear.

Purpose of the Study:

  • To investigate ceramide accumulation and function in CF lung macrophages.
  • To define the role of CFTR deficiency in macrophage response to Pseudomonas aeruginosa infection.

Main Methods:

  • Isolation and analysis of alveolar macrophages from wild-type (WT) and Cftr-deficient mice.
  • LysoSensor and tetramethylrhodamine dextran staining to characterize vesicle pH.
  • Assessment of acid sphingomyelinase activation, ceramide release, gp91(phox) clustering, and reactive oxygen species (ROS) production post-Pseudomonas aeruginosa infection.

Main Results:

  • Ceramide accumulates in Cftr-deficient lung macrophages.
  • Vesicles in Cftr-deficient macrophages exhibit higher pH, correlating with impaired acid sphingomyelinase activation and reduced ceramide release upon infection.
  • This leads to a failure in forming ceramide-enriched platforms, gp91(phox) clustering, and subsequent ROS production, hindering Pseudomonas aeruginosa killing.

Conclusions:

  • CFTR deficiency in lung macrophages leads to vesicular alkalinization, disrupting a pH-controlled pathway essential for ROS-mediated bacterial killing.
  • This identifies a novel mechanism by which CFTR dysfunction impairs macrophage antimicrobial function, contributing to CF lung pathology.